Camlipixant in refractory chronic cough: A Phase 2b, randomized, placebo-controlled trial (SOOTHE)

This Phase 2b, randomized trial evaluated the efficacy and safety of camlipixant versus placebo in 310 adult patients with refractory chronic cough. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency (coughs/hour), which was measured using the semi-automated Vitalograph VitaloJAK ambulatory cough monitor.